Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial May 16, 2024
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards April 19, 2024